Negative regulatory approaches to the attenuation of Toll-like receptor signaling

被引:114
作者
Anwar, Muhammad Ayaz [1 ]
Basith, Shaherin [1 ]
Choi, Sangdun [1 ]
机构
[1] Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, South Korea
基金
新加坡国家研究基金会;
关键词
inflammatory diseases; inhibitors; innate immune system; miRNA; Toll-like receptors; NF-KAPPA-B; TRIGGERED INFLAMMATORY RESPONSES; ARYL-HYDROCARBON RECEPTOR; I INTERFERON; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; DENDRITIC CELLS; CUTTING EDGE; PROTEIN; INNATE;
D O I
10.1038/emm.2013.28
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Toll-like receptors (TLRs) are pivotal components of the innate immune response, which is responsible for eradicating invading microorganisms through the induction of inflammatory molecules. These receptors are also involved in responding to harmful endogenous molecules and have crucial roles in the activation of the innate immune system and shaping the adaptive immune response. However, TLR signaling pathways must be tightly regulated because undue TLR stimulation may disrupt the fine balance between pro- and anti-inflammatory responses. Such disruptions may harm the host through the development of autoimmune and inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Several studies have investigated the regulatory pathways of TLRs that are essential for modulating proinflammatory responses. These studies reported several pathways and molecules that act individually or in combination to regulate immune responses. In this review, we have summarized recent advancements in the elucidation of the negative regulation of TLR signaling. Moreover, this review covers the modulation of TLR signaling at multiple levels, including adaptor complex destabilization, phosphorylation and ubiquitin-mediated degradation of signal proteins, manipulation of other receptors, and transcriptional regulation. Lastly, synthetic inhibitors have also been briefly discussed to highlight negative regulatory approaches in the treatment of inflammatory diseases. Experimental & Molecular Medicine (2013) 45, e11; doi:10.1038/emm.2013.28; published online 22 February 2013
引用
收藏
页码:e11 / e11
页数:14
相关论文
共 121 条
  • [1] TAK1 Negatively Regulates NF-κB and p38 MAP Kinase Activation in Gr-1+CD11b+ Neutrophils
    Ajibade, Adebusola Alagbala
    Wang, Qinfu
    Cui, Jun
    Zou, Jia
    Xia, Xiaojun
    Wang, Mingjun
    Tong, Yanzheng
    Hui, Wei
    Liu, Dou
    Su, Bing
    Wang, Helen Y.
    Wang, Rong-Fu
    [J]. IMMUNITY, 2012, 36 (01) : 43 - 54
  • [2] Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1
    An, Huazhang
    Hou, Jin
    Zhou, Jun
    Zhao, Wei
    Xu, Hongmei
    Zheng, Yuejuan
    Yu, Yizhi
    Liu, Shuxun
    Cao, Xuetao
    [J]. NATURE IMMUNOLOGY, 2008, 9 (05) : 542 - 550
  • [3] SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production
    An, Huazhang
    Zhao, Wei
    Hou, Jin
    Zhang, Yan
    Xie, Yun
    Zheng, Yuejuan
    Xu, Hongmei
    Qian, Cheng
    Zhou, Jun
    Yu, Yizhi
    Liu, Shuxun
    Feng, Gensheng
    Cao, Xuetao
    [J]. IMMUNITY, 2006, 25 (06) : 919 - 928
  • [4] The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling
    Ananieva, Olga
    Darragh, Joanne
    Johansen, Claus
    Carr, Julia M.
    McIlrath, Joanne
    Park, Jin Mo
    Wingate, Andrew
    Monk, Claire E.
    Toth, Rachel
    Santos, Susana G.
    Iversen, Lars
    Arthur, J. Simon C.
    [J]. NATURE IMMUNOLOGY, 2008, 9 (09) : 1028 - 1036
  • [5] Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
    Basith, Shaherin
    Manavalan, Balachandran
    Yoo, Tae Hyeon
    Kim, Sang Geon
    Choi, Sangdun
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2012, 35 (08) : 1297 - 1316
  • [6] In Silico Approach to Inhibition of Signaling Pathways of Toll-Like Receptors 2 and 4 by ST2L
    Basith, Shaherin
    Manavalan, Balachandran
    Govindaraj, Rajiv Gandhi
    Choi, Sangdun
    [J]. PLOS ONE, 2011, 6 (08):
  • [7] Toll-like receptor modulators: a patent review (2006-2010)
    Basith, Shaherin
    Manavalan, Balachandran
    Lee, Gwang
    Kim, Sang Geon
    Choi, Sangdun
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (06) : 927 - 944
  • [8] Macrophage glucocorticoid receptors regulate toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase
    Bhattacharyya, Sandip
    Brown, Diane E.
    Brewer, Judson A.
    Vogt, Sherri K.
    Muglia, Louis J.
    [J]. BLOOD, 2007, 109 (10) : 4313 - 4319
  • [9] RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3
    Brentano, F
    Schorr, O
    Gay, RE
    Gay, S
    Kyburz, D
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : 2656 - 2665
  • [10] ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance
    Brint, EK
    Xu, DM
    Liu, HY
    Dunne, A
    McKenzie, ANJ
    O'Neill, LAJ
    Liew, FY
    [J]. NATURE IMMUNOLOGY, 2004, 5 (04) : 373 - 379